J Endod:单锥核技术辅以Endosequence Bioceramic封闭剂的非手术根管治疗的临床效果观察

2018-04-16 lishiting MedSci原创

根管治疗的一个重要步骤是形成一个完整封闭的根管系统。EndoSequence BC封闭剂(BC; Brasseler USA, Savannah, GA)具有多种优秀特质,并且已成为从业者的常规封闭材料。到目前为止,还未有报道评估BC的临床成功率。这篇研究的目的是为了评估采用单锥核和BC技术进行非手术根管治疗的效果,并分析治疗成功或失败相关的因素。

根管治疗的一个重要步骤是形成一个完整封闭的根管系统。EndoSequence BC封闭剂(BC; Brasseler USA, Savannah, GA)具有多种优秀特质,并且已成为从业者的常规封闭材料。到目前为止,还未有报道评估BC的临床成功率。这篇研究的目的是为了评估采用单锥核和BC技术进行非手术根管治疗的效果,并分析治疗成功或失败相关的因素。

这项回顾性队列研究的对象为一家私人开业诊所2009-2015年间就诊的患者。所有病例,包括出诊和再治疗,均是采用BC和单锥核技术封闭充填,至少1年进行回访。分析患者和治疗因素以确定其作为预后因素的显着性。评估回访时基于临床和X线影像结果的疗效。牙齿分为:痊愈、愈合(成功)和未愈合(失败)。采用chi-square检验对潜在的愈合因素进行统计学评估(α = 0.05)。

结果显示,研究共对317颗牙齿进行了分析,平均随访时间为30.1个月。总体的治疗成功率为90.9%。损伤直径<5 mm的治疗成功率显著高于直径>5 mm的病例。封闭剂挤出根尖孔的病例占47.4%,并且封闭剂挤出对治疗效果没有任何明显的影响。

结论:采用BC和单锥核技术的封闭充填是一种可行的选择。

原始出处:

Chybowski EA, Glickman GN, et al. Clinical Outcome of Non-Surgical Root Canal Treatment Using a Single-cone Technique with Endosequence Bioceramic Sealer: A Retrospective Analysis. J Endod. 2018 Mar 29. pii: S0099-2399(18)30132-8. doi: 10.1016/j.joen.2018.02.019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918039, encodeId=86ab191803984, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 31 19:19:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2421, encryptionId=43df242149, topicName=AMIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jun 10 11:19:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738887, encodeId=dc041e3888790, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 04 07:19:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443044, encodeId=d4c61443044f3, content=<a href='/topic/show?id=674546e8323' target=_blank style='color:#2F92EE;'>#封闭剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46783, encryptionId=674546e8323, topicName=封闭剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5021004, createdName=12498dd9m12暂无昵称, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484485, encodeId=1cd4148448576, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522893, encodeId=7bbc15228938f, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
    2018-07-31 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918039, encodeId=86ab191803984, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 31 19:19:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2421, encryptionId=43df242149, topicName=AMIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jun 10 11:19:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738887, encodeId=dc041e3888790, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 04 07:19:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443044, encodeId=d4c61443044f3, content=<a href='/topic/show?id=674546e8323' target=_blank style='color:#2F92EE;'>#封闭剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46783, encryptionId=674546e8323, topicName=封闭剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5021004, createdName=12498dd9m12暂无昵称, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484485, encodeId=1cd4148448576, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522893, encodeId=7bbc15228938f, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
    2018-06-10 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918039, encodeId=86ab191803984, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 31 19:19:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2421, encryptionId=43df242149, topicName=AMIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jun 10 11:19:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738887, encodeId=dc041e3888790, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 04 07:19:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443044, encodeId=d4c61443044f3, content=<a href='/topic/show?id=674546e8323' target=_blank style='color:#2F92EE;'>#封闭剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46783, encryptionId=674546e8323, topicName=封闭剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5021004, createdName=12498dd9m12暂无昵称, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484485, encodeId=1cd4148448576, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522893, encodeId=7bbc15228938f, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918039, encodeId=86ab191803984, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 31 19:19:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2421, encryptionId=43df242149, topicName=AMIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jun 10 11:19:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738887, encodeId=dc041e3888790, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 04 07:19:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443044, encodeId=d4c61443044f3, content=<a href='/topic/show?id=674546e8323' target=_blank style='color:#2F92EE;'>#封闭剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46783, encryptionId=674546e8323, topicName=封闭剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5021004, createdName=12498dd9m12暂无昵称, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484485, encodeId=1cd4148448576, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522893, encodeId=7bbc15228938f, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918039, encodeId=86ab191803984, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 31 19:19:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2421, encryptionId=43df242149, topicName=AMIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jun 10 11:19:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738887, encodeId=dc041e3888790, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 04 07:19:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443044, encodeId=d4c61443044f3, content=<a href='/topic/show?id=674546e8323' target=_blank style='color:#2F92EE;'>#封闭剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46783, encryptionId=674546e8323, topicName=封闭剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5021004, createdName=12498dd9m12暂无昵称, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484485, encodeId=1cd4148448576, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522893, encodeId=7bbc15228938f, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1918039, encodeId=86ab191803984, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 31 19:19:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2421, encryptionId=43df242149, topicName=AMIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jun 10 11:19:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738887, encodeId=dc041e3888790, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 04 07:19:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443044, encodeId=d4c61443044f3, content=<a href='/topic/show?id=674546e8323' target=_blank style='color:#2F92EE;'>#封闭剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46783, encryptionId=674546e8323, topicName=封闭剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5021004, createdName=12498dd9m12暂无昵称, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484485, encodeId=1cd4148448576, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522893, encodeId=7bbc15228938f, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Wed Apr 18 11:19:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]